Home Contact News

News

Find out more …

FAQs
News
ROVI up to date
Contact
Filter results
E.g., 24/10/2024
E.g., 24/10/2024
24/10/2024
ROVI completes the strategic review of its CDMO business
31/07/2024
First half 2024 results press release
ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS
Download
11/07/2024
ROVI invests 60 million euros to expand the production capacity of its San Sebastián de los Reyes plant by 31.5%
The Community of Madrid has declared this project to be strategic: it will create 200 new direct jobs for 2027 and raise the plant’s production capacity to 500 million injectables
24/06/2024
ROVI forecasts potential Risperidone ISM® sales of between 200 and 300 million euros globally in upcoming years
20/06/2024
ROVI completes its new Escúzar plant by including a sodium heparin production facility
ROVI reinforces its heparin production capacity
08/05/2024
First three months 2024 results press release
ROVI closes the quarter with operating revenue of 151.2 million euros
Download
25/04/2024
ROVI announces agreement to manufacture pre-filled syringes
Agreement to manufacture pre-filled syringes for a global pharmaceutical company
Download
02/04/2024
ROVI receives the FDA’s approval of Risvan® as a treatment for schizophrenia
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults
Download
12/03/2024
ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies
This public-private collaboration instrument falls within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE) and will have an initial investment of over 74 million euros
Download

Pages